For the treatment of type 2 diabetes, GLP-1 mimetics and GLP-1 degradation inhibitors (DPP4 inhibitors) are many, and GLP-1 mimetics are also licensed [133]. This evidence concerns the gene GCG and type 2 diabetes mellitus.